Kane Biotech Expands revyve™ Gel Product Line
Company Announcements

Kane Biotech Expands revyve™ Gel Product Line

Story Highlights

Kane Biotech (TSE:KNE) has released an update.

Kane Biotech Inc. has announced the expansion of its revyve™ Antimicrobial Wound Gel product line, backed by up to $200,000 in funding from the NRC IRAP, to develop three new products. These products aim to increase the company’s market presence by offering solutions for different types of wounds and settings, which will potentially drive higher revenue through increased price points and volumes.

For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskKane Biotech Bolsters Capital with Warrant Exercise
GlobeNewswireKane Biotech Announces Exercise of Warrants
TipRanks Canadian Auto-Generated NewsdeskKane Biotech Reports Strong Q2 with Major Gains
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App